Home
The Department of Biomedicine

News archive for The Department of Biomedicine

The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
Meg Veruki and Espen Hartveit from the Retinal Microcircuits Research Group at the Department of Biomedicine have been chosen to be the Visionaries of the Quarter for the European Vision Institute.
Welcome to a 2-days workshop 17.-18. Oct. with the Andor Academy team and Bitplane (Imaris) representatives.
The post-synaptic protein Arc has been termed a master regulator of memory. In line with its homology to certain viral proteins, it has also been shown recently to form virus-like capsids. We have elucidated for the first time the 3D structure of full-length monomeric Arc.
Thanks to funding from the Faculty of Medicine MIC recently got a new confocal in house. It was installed before summer and is ready to use.
Open for registration, deadline 23rd of February.
Bortezomib as chemosensitizer for glioblastoma patients with unmethylated MGMT promoter: Phase IB/II clinical trial and mechanisms of therapeutic efficacy
A state-of-the-art imaging system for high-throughput crystallization experiments has been installed at BiSS at the Department of Biomedicine. The system is capable of imaging samples using both visible and UV light. The imager is a significant addition to the crystallization laboratory as well as BiSS, providing a seamless workflow from the Mosquito LCP pipetting robot to automated imaging. It... Read more
The Workshop in Applied Structural Bioinformatics will be organized at the University of Bergen October 16-20. This workshop will provide a practical introduction to popular tools for biomolecular visualisation, analysis and simulations. Lectures will be given by both international and local speakers from the research fields of structural bioinformatics and computer-aided drug design.
The Shank family of proteins functions as a molecular scaffold in the neuronal post-synaptic density, enabling numerous protein-protein interactions. Shanks are large multi-domain molecules, and one of the conserved domains is an SH3 domain. Using high-resolution X-ray crystallography, we show that the SH3 domain in the Shank family has lost its canonical ligand-binding site.
Sarsia Seed recently announced their new seed funds in Bergen consisting of 300 million NOK. Initial investment can be in the biotechnology company Pluvia founded by Prof. Aurora Martinez according to Sarsia officials.

Pages